United Therapeutics Corporation Stock News

United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

While the top- and bottom-line numbers for United Therapeutics (UTHR) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metric

United Therapeutics (UTHR) came out with quarterly earnings of $5.24 per share, beating the Zacks Consensus Estimate of $4.41 per share. This compares to earnings of $2.41 per share a year ago.

The biotechnology industry is simply amazing, always advancing and bringing new drugs to fight complicated and serious diseases. If you are thinking about investing in this sector, it is crucial to kn

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its second quarter 2023 financial results before

United Therapeutics (UTHR) came out with quarterly earnings of $4.86 per share, beating the Zacks Consensus Estimate of $4.35 per share. This compares to earnings of $5.03 per share a year ago.

Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2023 financial results before t

Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indi

Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.

With the goal of generating strong risk-adjusted returns and capital appreciation, Bernard Horn (Trades, Portfolio)'s Polaris Capital Management invests in discounted but high-quality stocks in develo

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperso

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and

United Therapeutics' (UTHR) fourth-quarter earnings and sales miss estimates. Tyvaso sales continue to drive the company's top line.

United Therapeutics Corporation (NASDAQ:UTHR ) Q4 2022 Earnings Conference Call February 22, 2023 9:00 AM ET Company Participants Dewey Steadman - Head-Investor Relations Martine Rothblatt - Chairpers